The vaccine trial, which was developed in cooperation with the German Center for Infection Research (DZIF), will be conducted on 30 participants between the ages of 18 and 55, who will receive two vaccines every four weeks.
A larger trial for the second phase, which will include elderly volunteers, is scheduled for the end of this year, if the results of the early phase study show that the vaccine is safe and produces an immune response.
IDT Biologika, an unlisted company headquartered in Dessau Rosslau in eastern Germany, produces viral vaccines for pharmaceutical companies and assists with six projects related to “Covid-19”, including AstraZeneca’s experimental vaccine against the Corona virus.
This so-called viral vector vaccine is approved
Its vaccine, based on a modified, harmless smallpox virus, has already been used to develop a vaccine against the Coronavirus that causes Middle East Respiratory Syndrome (MERS).
Hundreds of potential “Covid-19” vaccines are in various stages of development, with 41 of them in human trials around the world, including Russia and China.
Germany has awarded vaccine makers BioNTech and CureVac 627 million euros ($ 734.78 million) to help speed up work on the “Covid-19” vaccine and increase German production capacity. It is currently in talks with IDT Biologika about providing funding for it as well.
These were the details of the news German company launches third vaccine trial against “Covid-19” for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at saudi24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.